Osteopontin (OPN) is a multifunctional bone matrix glycoprotein that is involved in angiogenesis, cell survival and tumor progression. In this study we show that human myeloma cells directly produce OPN and express its major regulating gene Runx2/Cbfa1. The activity of Runx2/Cbfa1 protein in human myeloma cells has also been demonstrated. Moreover, using small interfering RNA (siRNA) to silent Runx2 in myeloma cells, we suppressed OPN mRNA and protein expression. OPN production in myeloma cells was stimulated by growth factors as IL-6 and IFG-1 and in turn OPN stimulated myeloma cell proliferation. In an 'in vitro' angiogenesis system we showed that OPN production by myeloma cells is critical for the proangiogenic effect of myeloma cells. The expression of OPN by purified bone marrow (BM) CD138 þ cells has also been investigated in 60 newly diagnosed multiple myeloma (MM) patients, finding that 40% of MM patients tested expressed OPN. Higher OPN levels have been detected in the BM plasma of MM patients positive for OPN as compared to controls. Moreover, significantly higher BM angiogenesis has been observed in MM patients positive for OPN as compared to those negative. Our data highlight that human myeloma cells with active Runx2/Cbfa1 protein directly produce OPN that is involved in the pathophysiology of MM-induced angiogenesis.
Introduction
Growing evidence suggests that an increase of bone marrow (BM) angiogenesis may contribute to multiple myeloma (MM) cell growth, survival and progression. [1] [2] [3] The angiogenic switch in MM patients mainly depends on the production of proangiogenic factors by myeloma cells or by the microenvironment. 2 Among the proangiogenic molecules, VEGF, basic FGF (bFGF) and more recently angiopoietin-1 (Ang-1) have been implicated in the pathophysiology of myeloma-induced angiogenesis. [4] [5] [6] Osteopontin (OPN) is a multifunctional bone matrix associated glycoprotein secreted by many cell types including lymphocytes, osteoclasts, endothelial cells and tumoral cells. 7 OPN expression by human cells is mainly regulated by the bone-specific transcription factor Runx2, namely also Cbfa1 (Runx2/Cbfa1), as demonstrated in bone cells, normal mammary cells and breast cancer cells. [8] [9] [10] [11] Two different isoforms (Runx2/ Cbfa1/I and Runx2/Cbfa1/II) have been described in human osteoblastic cells, both able to regulate OPN expression. 11 However, other transcription factors may also be involved in the production of OPN by cancer cells as the CCAAT/enhancerbinding protein alpha (C/EBPa) and AML-1, because it has been demonstrated that OPN promoter contains their DNA binding consensus regions. 12 OPN interacts with CD44 as a major receptor promoting cell adhesion, proliferation and survival. 7, 13 Recent data indicate that OPN also stimulates endothelial cell survival and migration [13] [14] [15] and acts as a potent proangiogenic factor in vivo. 16, 17 In several solid tumors it has been shown that OPN is overexpressed and promotes tumoral growth, angiogenesis and progression. 18, 19 Recently, high OPN levels have been demonstrated in MM patients; therefore, OPN production by BM mononuclear cells or by myeloma cells has been hypothesized. 20, 21 However, the direct production of OPN and the expression and the activity of its major regulating gene Runx2/Cbfa1 in myeloma cells as well as the potential role of OPN in MM-induced BM angiogenesis have to be elucidated.
Methods

Reagents
Recombinant human (rh)IL-6, rhIGF-I, rhTNF-a and rhVEGF were obtained by Endogen (Woburn, MA, USA). rhOPN was purchased from R&D Systems (Minneapolis, MN, USA). Culture media RPMI-1640, aMEM, D-MEM and TC 199 as well as glutamine, penicillin and streptomycin and fetal bovine serum (FBS) were purchased from Invitrogen Life Technologies (Milan, Italy).
Cells and cell conditions
Human myeloma cell lines (HMCLs) XG-6 and XG-1 were established from peripheral blood of patients with plasma cell leukemia in Dr Bataille's laboratory (INSERM, Nantes, France). U266 was obtained from the American Type Culture Collection (Rockville, MD, USA); OPM-2, RPMI-8226 and the EBV þ cell line ARH-77 were purchased from DSM (Braunschweig, Germany). Human trabecular SV-40-transfected osteoblasts (HOBIT) were a kind gift from Dr Riggs (Mayo Clinic, Rochester, MN, USA).
HMCLs (5 Â 10 6 ) were incubated in the presence or absence of IL-6 (20 ng/ml), IGF-I (100 ng/ml), TNF-a (100 ng/ml) or VEGF (50 ng/ml) for 24-48 h; thereafter, conditioned medium (CM) and cellular pellets were stored at -801C.
In some experiments, XG-1, XG-6, U266 were treated with OPN (100 ng/ml-1 mg/ml) in the presence or absence of IL-6 (20 ng/ml) for 48-72 h with or without anti-OPN mAb (ImmunoBiological Laboratories Co. (IBL), Japan). To perform the immunodepletion of OPN, the CM of HMCLs was incubated either with 0.5 mg of anti-OPN mAb (Assay Designs, IncAnn Arbor, MI, USA) or with control antiserum for 1 h at 41C; then 20 ml of Protein G PLUS-Agarose (Santa Cruz Biotechnology, DBI, Milan, Italy) was added and incubated with mixing for 2 h at 41C. The resulting immune complexes were removed by centrifugation, the supernatant was transferred to a fresh tube, and the immunodepletion process was repeated two more times. Thereafter, we tested VEGF and OPN levels in the CM by ELISA after the immunodepletion. The final OPN-depleted medium was then tested for its ability to stimulate vessel formation in vitro. 3 
H-thymidine incorporation
HMCL proliferation was determined in 96-well microtiter plates. 10 5 cells per well were incubated for 3 days and pulsed with 0.0185 MBq of 3 H-thymidine ( 3 H-TdR) for 12 h before cell harvesting on glass fiber filter paper. Uptake of 3 H-TdR was measured in a liquid scintillation counter. Each condition was performed in six replicate wells and the results were expressed as the mean counts per minute7standard error of the mean (cpm7s.e.).
In vitro angiogenesis assay
In vitro angiogenesis was assessed by Angio-kit obtained from TCS Biologicals (Buckingham, UK) as previously described. 6 Briefly, cells were stimulated with VEGF (2 ng/ml) or rhOPN (50-500 ng/ml) or with CM of HMCLs/D-MEM at 10% FBS (ratio 1:2) in the presence or absence of blocking anti-OPN mAb (IBL), anti-Tie2 blocking polyclonal Ab (5 mg/ml) (R&D Systems, Minneapolis, MN, USA), anti-bFGF (1 mg/ml) (R&D Systems), anti-VEGF (2 mg/ml) (R&D Systems) or anti-IgG control Ab. Similarly, we tested the effect of OPN-immunodepleted CM of HMCLs/D-MEM 10% FBS in the presence or absence of rhOPN. At day 11, cells were fixed and stained using an anti-CD31 Ab (TCS Biologicals) according to the instructions provided. To measure the formation of the capillary network, the number of connections between three or more capillary-like structures was considered and plates were quantified by a computerized image analysis (TCS Biologicals).
Patients
We studied 60 patients with newly diagnosed or relapsed MM in stage I-III. BM aspirates and bone biopsies were obtained from iliac crest of all patients after informed consent according to the Declaration of Helsinki. BM CD138 þ plasma cells were purified from isolated mononuclear cells (MNC) with an immunomagnetic method using anti-CD138 mAb-coated microbeads (MACS, Miltenyi Biotec, Bergisch-Gladbach, Germany). Only samples with purity 490%, checked by flow cytometry, were tested. Fresh MM cells were analyzed immediately after purification. CD19 þ cells obtained from healthy subjects were used as control. BM stromal cells (BMSC) were obtained from BM MNC of both MM patients after CD138
þ depletion (MACS, Miltenyi) and healthy subjects as previously described. 6 Moreover, BM plasma was obtained from MM patients (n ¼ 30) and from a cohort of normal subjects or monoclonal gammopathy of undetermined significance (MGUS) patients (n ¼ 20).
RNA isolation and reverse-transcriptase (RT)-PCR amplification
For RT-PCR analysis, total cellular RNA was extracted from cells using Trizol reagent (Invitrogen). In total, 1 mg of RNA was reverse-transcribed with 400 U of Moloney murine leukemia virus reverse transcriptase (Invitrogen) according to the manufacturer's protocol. cDNAs were amplified by PCR with specific primer pairs. For C/EBPa amplification, mRNA was pretreated with DNasi (Invitrogen) to avoid DNA contamination because C/EBPa gene has no intron regions. PCR reactions were performed in a thermal cycler ( 6 Pictures of the electrophoresed cDNAs were recorded with a digital DC 120 Kodak camera and quantified as previously described. 6 
siRNA transfection
Before electroporation, HMCL cells were washed twice with serum-free Opti-MEM (Gibco BRL Paisley, UK) and resuspended to a final concentration of 2 Â 10 7 cells/ml in Opti-MEM (Gibco BRL). Subsequently, 0.4 ml of cell suspension was mixed either with 1 nmol of a Smart pool double-stranded RNA oligonucleotide (siRNA) against Runx2 (M-012665-00) or nonspecific control siRNA (D-001206-13-05) obtained from Dharmacon Tech (Lafayette, Co) and electroporated in a 0.4-cm cuvette using the Gene Pulser electroporation apparatus (Bio-Rad Laboratories Inc., Herculex, CA, USA) using a single-pulse protocol (voltage 250 V and capacitance 1050 mF for U266 and RPMI-8226 or voltage 210 V and capacitance 900 mF for XG-1 and XG-6 cell lines). At 24 and 48 h after the transfection, cells were harvested for Runx2 and OPN mRNA and protein expression. The viability of HMCLs after the transfection was evaluated by flow cytometry.
Extraction of nuclear proteins and gel mobility shift assay (EMSA) turer's protocol. Gel mobility shift assay was performed, using a Nushift AML-3/Runx2 kit (Active Motif). Briefly, Runx2/Cbfa1 binding consensus oligonucleotide probes (OSE2: 5-AGCTG CAATCACCAACCACAGCA-3) were annealed by heating to 951C and cooling to 251C in 50 mM Tris-HCl (pH 8.2), 10 mM MgCl 2 and 1 mM EDTA, end-labeled with [32P]dCTP and purified through a G-25 purification column (Active Motif). Nuclear extracts (20 mg) were incubated on ice for 10 min in binding buffer (20 mM HEPES-HCl, 0.1 M KCl, 1 mM DTT, 1 mM EDTA, 0.5 mg/ml BSA, 50 mg/ml poly(dI/dC) and 20% glycerol, pH 7.9) with 10 fmol (2 Â 10 4 cpm) of 32P-labeled doublestranded oligonucleotide probes in a total volume of 20 ml. In competitive binding reactions, unlabeled wild-type oligonucleotide was added before the 32P probe. Protein-DNA complexes were resolved in 5% nondenaturing polyacrylamide gels in Tris-glycine buffer (25 mM Tris, 192 mM glycine, pH 8.3) at 201C, 25 mA, and 200 V for 1.5 h. Supershift experiments contained 0.2 mg Runx2/Cbfa1 polyclonal rabbit antibody supplied with the kit. Gels were dried and analyzed by autoradiography.
Quantitative AML-1 and Runx2/Cbfa1 binding activity was further assessed by an ELISA-based assay as previously described 22, 23 (TransAM Runx2 and TransAM AML-1, Active Motif, Vinci Biochem, Florence, Italy) according to the manufacturer's procedures. Nuclear extracts of human cell lines Saos2 and HL-60 with or without wild-type (WT) or mutated (MT) consensus-specific oligonucleotides were tested as controls for Runx2 and AML-1 activity, respectively.
Western blot analysis and immunoprecipitation
Western blot analysis and immunoprecipitation were performed on cell lysates as previously described. 6 Anti-OPN mAb (1:50) (Assay Designs), anti-Ang-1 polyclonal Ab (Santa Cruz Biotechnology) and b-actin (1:500) (Sigma Aldrich, St Louis, MO, USA) were used as primary antibodies. Runx2/Cbfa1 and AML-1 protein expression was detected on 80 mg of nuclear extracts of HMCLs using as primary antibody either a rabbit polyclonal anti-Runx2/Cbfa1 Ab (Santa Cruz, sc-10758) (dilution 1:100) or a goat polyclonal anti-AML-1 Ab (Santa Cruz, sc-8563) (1:100).
FACS analysis
Fluorescein isothiocyanate-conjugated (FITC-conjugated) and phycoerythrin-conjugated (PE-conjugated) mAbs or CyChromeconjugated mAbs recognizing CD138, CD44 or CD19 and the negative controls of IgG1 or IgG2a isotype of irrelevant specificity were purchased from Becton Dickinson (San Jose, CA, USA). To evaluate cell survival, HMCLs were permeabilized in 90% ethanol and 10% PBS and then incubated with 50 mg/ml propidium iodide (PI), 100 U/ml RNase A (Sigma Aldrich), 0.1% Nonidet P-40 and 0.1% trisodium citrate for 30 min before analysis using a Becton Dickinson FACSort analyzer. Cells with a hypodiploid DNA content (o2n, 40.2n) were counted as apoptotic. Detection of phosphatidylserine on the outer leaflet of apoptotic cells was performed using Annexin V-FITC (Becton Dickinson) and PI according to the manufacturer's recommendations.
ELISA assay
Soluble OPN was detected in the CM of HMCLs and in BM plasma of both MM patients and control subjects using an ELISA assay purchased from IBL. OPN levels in the CM were normalized for the number of cells at the end of the culture period. The interassay coefficient of variation (CV) was 7.56% and the intra-assay CV was 8%. The range of sensibility of the assay was 5-320 ng/ml. Soluble VEGF was measured by a commercially available assay kit (R&D system, Minneapolis, MN, USA) as previously described. 6 
BM angiogenesis evaluation
Blood vessels were detected in 3 mm sections of 4% formalin and B5 solution-fixed paraffin embedded biopsies. Angiogenesis was measured as density of microvessels (capillaries and small venules) by staining endothelial cells using anti-CD34 monoclonal Ab (working dilution 1:50, clone QBEnd/10 NeoMarkers, Fremont, CA, USA) after antigen retrieval treatment performed by three microwave cycles (5 min each one) in citrate buffer pH 6.0 at 650 W. Thereafter, the above-mentioned peroxidase method was used. In the whole section of biopsy, all the transversal sections of vessels were counted at 400 Â magnification: those that did not exceed 7 mm were recorded as capillaries, whereas those that did not exceed 10 mm were recorded as small venules. The computerized image analysis (FOTOVIX TAMRON, using Image Pro Plus Window 4.5) was applied to measure the diameter of microvessel transversal section and the total cellular area in mm 2 (biopsy total area minus dense connective tissue, fat, bone lamellae, necrosis hemorrhagic areas). The mean of vascular density and the mean number of microvessels in each biopsy were expressed on the basis of total number of microvessel transversal section (capillaries and/or venules) per total cellular area (in mm 2 ) and per total number of fields (400 Â magnification), respectively.
Results
Expression and production of OPN by myeloma cells: upregulation by IL-6
First, we evaluated the expression of OPN mRNA by HMCLs. We found that RPMI-8226, U266, XG-1 and XG-6 express OPN whereas OPM-2 and ARH-77 were negative as well as CD19 As control, Ang-1 expression by RPMI-8226 was used showing that IL-6 did not modify its expression as we have previously published. 6 In addition, IL-6 stimulation significantly upregulated OPN secretion by RPMI-8226 (mean7s.e. vs control: 476.85712.51 vs 24.2274.74 ng/ml, Po0.001) and IGF-I induced a slight stimulatory effect (mean7s.e. vs control: 77.571.23 vs 24.2274.74 ng/ml, P ¼ 0.05) as well as VEGF (117.873.53 vs 24.2274.74 ng/ml, P ¼ 0.05), whereas TNF-a (P ¼ NS) had no effect (Figure 1f ). Similar effects were observed using the other HMCLs (data not shown).
Expression and activity of the transcription factor Runx2/ Cbfa1 by myeloma cells and its role in OPN expression
Since it has been demonstrated that either in osteoblastic cells or in breast cancer cells OPN production is regulated by the transcription factor Runx2/Cbfa1, for the first time we have investigated the potential expression and activity of Runx2/ Cbfa1 in myeloma cells. Among the HMCLs tested, we found that RPMI-8226, U266, XG-1 and XG-6 expressed Runx2/Cbfa1 mRNA whereas only OPM-2 was negative (Figure 2a) in line with the different production of OPN by these HMCLs (Figure 1 ). Since two different Runx2/Cbfa1 isoforms have been demonstrated in human bone cells, we performed a PCR with two specific primer pairs showing that HMCLs express the Runx2/ Cbfa1 isoform II but not the isoform I (data not shown).
The expression of other transcription factors that could be involved in OPN production as C/EBPa, AML-1A and AML-1B mRNA has also been investigated in HMCLs. We found that all HMCLs tested were negative for C/EBPa mRNA (Figure 2a) , whereas AML-1A and/or AML-1B mRNA were expressed in all HMCLs (Figure 2a ) even if any correlation has not been found between OPN expression and AML-1A/AML-1B ratio as demonstrated by densitometry (data not shown). The expression of Runx2/Cbfa1 and AML-1 by HMCLs was confirmed by Western blot analysis on nuclear extracts. We found that RPMI-8226, XG-1, U266 and XG-6 expressed Runx2 while OPM-2 was negative and, on the contrary, all the HMCLs tested were positive for AML-1 protein (Figure 2b) .
To determine the activity of Runx2/Cbfa1 in human myeloma cells, nuclear extracts were prepared from HMCLs and the DNA binding activity was assessed by EMSA using an oligonucleotide probe containing the Runx2/Cbfa1 binding consensus sequence. HOBIT were used as positive control (Figure 2c, line 1) . The DNA binding was significantly competed away by the addition of a 100-fold excess of unlabeled wild-type competitor ( Figure 2c , line 2) but not by the addition of a 100-fold excess of unlabeled mutant probe (Figure 2c, line 3) . Moreover, the specificity of the DNA binding was demonstrated by þ cells from healthy donors were used as positive and negative control, respectively, and b 2 -microglobulin was amplified as internal control (a). OPN protein production by HMCLs has been checked by Western blot analysis on myeloma cell lysates (b on the top) and by immunoprecipitation performed on HMCLs conditioned medium (b on the bottom), as described in the 'Methods'. OPN levels were evaluated by ELISA assay on aliquots of conditioned medium of HMCLs (1 Â 10 6 /ml) (c). RPMI-8226 (5 Â 10 6 ) cells were incubated in the presence or absence of IL-6 (20 ng/ml), IGF-I (100 ng/ml), TNF-a (100 ng/ml) or VEGF (50 ng/ml). After 24 h, mRNA was extracted and OPN mRNA expression was analyzed by RT-PCR and quantified by densitometry (d). Graphs represent the mean OD7s.d. of three quantifications of three independent experiments. After 48 h, OPN and Ang-1 proteins were assessed in cell lysates by Western blot (e). OPN soluble levels were detected in the conditioned medium by ELISA and normalized to the number of cells at the end of the culture period (f). Graphs represent the mean7s.e. of OPN levels of three independent experiments.
supershifting the Runx2/Cbfa1-DNA complex by the addition of antibody against Runx2/Cbfa1 (Figure 2c Runx2/Cbfa1 expression and activity in myeloma cells. The expression of Runx2/Cbfa1, C/EBPa, AML-1A and AML-1B mRNA was evaluated by RT-PCR in RPMI-8226, U266, XG-1, OPM-2 and XG-6 as well as in fresh purified CD138 þ plasma cells, as shown for four representative MM patients (a). Nuclear extracts (80 mg) were obtained from RPMI-8226, XG-1, OPM-2, U266, XG-6 and human osteoblasts (hOB) and analyzed for Runx2/Cbfa1 and AML-1 protein expression by Western blot as described in the 'Methods' section. Runx2/Cbfa1 was identified as a band of molecular weight of about 65 kDa (b). Runx2/Cbfa1 DNA binding activity was evaluated in hOB and HMCLs XG-6, OPM-2 and RPMI-8226 by EMSA. Line 1: hOB; line 2: hOB plus 100-fold wild-type unlabeled probe; line 3: hOB plus 100-fold mutant unlabeled probe; line 4: hOB plus antibody specific for Runx2/Cbfa1; line 5: XG-6; line 6: probe alone; line 7: probe plus antibody; line 8: OPM-2; line 9: RPMI-8266 (c). Runx2 (d on the top) and AML-1 (e) activity was quantified in HMCLs (RPMI, XG-1, OPM-2, U266 and XG-6) by Transcription factor assay kit as described in the 'Methods' section. Nuclear extracts of human cell lines Saos2 and HL-60, in the presence or absence of wild-type (WT) or mutated (MT) competitor oligonucleotides, were tested as controls for Runx2 and AML-1 activity, respectively, according to the manufacturer's recommendations. Graphs represent the mean7s.d. of Runx2 and AML-1 activity normalized to 10 mg of protein analyzed of two independent experiments performed in triplicate (OD ¼ optical density). Runx2 protein expression was analyzed in cell lysates by Western blot analysis (d on the bottom). Runx2 activity was quantified in nuclear extracts of RPMI and XG-1 after 24 h stimulation with IL-6 (20 ng/ml) or IGF-I (100 ng/ml). Graphs represent the mean % fold induction 7s.d. of Runx2 activity vs control (normalize to 1) of two independent experiments performed in triplicate (OD ¼ optical density) ( n Po0.05) (f).
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Runx2 was further confirmed in HMCLs by TransAM ELISA assay finding a significant activity of Runx2 in HMCLs that produce OPN but not in the negative one, OPM-2 ( Figure 2d) . A different pattern of Runx2 activity was observed in HMCLs consistently with the level of Runx2 protein (Figure 2d) . On the contrary, we found that AML-1 did not show a significant activity in HMCLs as compared to the positive control (HL-60 cell line) (Figure 2e ). Finally, we found that IL-6 and IGF-I significantly increased the activity of Runx2 in RPMI-8226 and XG-1 (Figure 2f ) but they did not modify AML-1 activity (data not shown). To demonstrate that Runx2 is involved in OPN production by myeloma cells, the Runx2 mRNA was selectively knocked down in HMCLs by specific double-stranded RNA oligonucleotides (siRNA). The transfection with Runx2 siRNA, but not with the nonspecific control siRNA, led to decreased Runx2 mRNA expression in HMCLs as shown for RPMI-8226 and XG-6 ( Figure 3a) . As expected, Runx2 siRNA inhibited both Runx2 activity (Figure 3b ) and protein in HMCLs as shown for XG-6 and RPMI-8226 without affecting the levels of AML-1 protein.
In line with our hypothesis, we found that the block of Runx2 expression by siRNA transfection suppressed OPN mRNA expression ( Figure 3a ) and OPN protein expression and secretion by HMCLs as shown for XG-6 and RPMI-8226 ( Figure 3c ).
Effect of OPN on myeloma cell proliferation
To investigate whether OPN could affect myeloma cell proliferation and survival, first we checked CD44 expression on myeloma cells by FACS and we found that all HMCLs tested XG-6, XG-1, U266, RPMI-8226 and OPM-2 express CD44 (Figure 4a ). The presence of rhOPN in culture medium at concentrations ranging from 100 ng/ml to 1 mg/ml significantly increased the (Figure 4b ). On the contrary, any significant effect was not observed on HMCLs survival by OPN treatment both in the presence and absence of IL-6 in the culture (data not shown).
Role of OPN in HMCL-induced in vitro angiogenesis
The potential role of OPN in MM-induced angiogenesis has been investigated in an experimental model of angiogenesis. As expected, VEGF (2 ng/ml) stimulated vessel formation in comparison with control, whereas suramin (20 mM) inhibited tubule formation (data not shown). In this system, rhOPN treatment stimulated vessel formation as compared to control (Figure 5a, b To investigate the potential role of OPN in myeloma-induced angiogenesis, first we performed OPN immunodepletion of HMCLs CM. Any significant difference of VEGF levels was not Role of Runx2 in the regulation of OPN expression and production by myeloma cells. RPMI-8226 and XG-6 were transfected by electroporation with 1 nmol of Smart pool double-stranded RNA oligonucleotides (siRNA) against Runx2 or nonspecific control siRNA (CY) as described in the 'Methods' section. After 24 h, cells were harvested for Runx2 and OPN mRNA evaluation by RT-PCR (a) and Runx2 binding activity on nuclear extracts. Graphs represent the mean7s.d. of Runx2 activity normalized to 10 mg of protein of two independent experiments performed in triplicate (OD ¼ optical density) ( n Po0.01) (b). Runx2, AML-1 and OPN protein expression was evaluated in nuclear extracts and cytoplasmatic lysates of XG-6 and RPMI-8226 by Western blot (c).
Pro-angiogenic effect of OPN in multiple myeloma S Colla et al observed after the OPN immunodepletion in the CM of RPMI-8226 (mean7s.d.: 1350718 vs 1260750 pg/ml; P ¼ NS). On the contrary, OPN levels were completely abolished (24.2274.74 ng/ml vs undetectable).
Thereafter, we tested the OPN-immunodepleted CM of RPMI-8226 in the angiogenesis in vitro assay finding that it had no stimulatory effect on vessel formation as compared to the nonimmunodepleted one (Figure 4d) (Figure 5f ), whereas an irrelevant antibody anti-IgG had no effect. A similar inhibitory effect was observed with the presence of blocking anti-VEGF mAb and anti-Tie-2 polyclonal Ab (data not shown), as previously published. 6 
Expression of OPN in fresh purified MM cells and BM OPN levels in MM patients
To address our in vitro results into a clinical perspective, first we tested OPN mRNA expression by high-purified CD138 þ MM cells obtained from 60 consecutive newly diagnosed MM. OPN expression was determined at both mRNA and protein level by RT-PCR and by Western blot analysis, respectively, as shown for four representative patients in Figure 6A . We found that 24 MM patients out of 60 tested (40%) were positive for OPN (Table 1) , 33 out of 60 expressed Ang-1 mRNA (55%) and almost all patients tested (90%) were positive for VEGF mRNA. On the other hand, bFGF mRNA was expressed in about 30% of patients analyzed as previously published. 24 Comparing OPN and Ang-1 expression in our cohort of MM patients, a different pattern of expression was observed. In fact, we found that 75% of MM patients positive for OPN also expressed Ang-1, whereas the 52% of MM patients negative for OPN did not express Ang-1.
BMSC isolated from all MM patients also expressed OPN but any difference in OPN expression has not been found between BMSC obtained from MM patients and normal subjects (data not shown). On the other hand, we found that OPN levels were significantly higher in BM plasma of MM patients positive for OPN as compared to normal subjects (median levels vs control: 140 vs 64 ng/ml; 25th-75th percentile vs controls: 113-217 vs 59-86 ng/ml; Po0.05) (Figure 6B ), whereas MM patients negative for OPN had no significantly higher OPN levels as compared to controls (data not shown). In 31 MM patients, we have also tested Runx2/Cbfa1 mRNA expression, as shown for four representative patients in Figure 2a , and we found a significant correlation (P ¼ 0.01) between Runx2/Cbfa1 and OPN mRNA expression, as observed for HMCLs. Pro-angiogenic effect of OPN in multiple myeloma S Colla et al
Relationship between OPN expression and BM angiogenesis in MM patients
Further, BM angiogenesis was evaluated in bone biopsies obtained from MM patients. As expected, we found that the microvascular density (MVD) was significantly higher in MM patients as compared to control group (mean7s.e.: 25.0970.28 vs 1070.1; Po0.001). A significant increase of the MVD was observed in the group of patients positive for OPN (mean7s.e.: 29.170.7 vs 17.5570.37; Po0.01) ( Table 1) . Similarly, the number of microvessels per field ( Â 400) was higher in OPNpositive patients in comparison with OPN-negative ones (mean7s.e.: 6.770.15 vs 4.2870.04; P ¼ 0.05) ( Table 1) . A significantly positive correlation between OPN expression and MVD was also found in our cohort of MM patients (Pearson w 2 : P ¼ 0.03; Cochran's linear trend: P ¼ 0.015). In Figure 6C , BM angiogenesis of two representative patients, negative (a) or positive (b) for OPN expression, has been shown, respectively. On the other hand, any difference was not observed between OPN-positive and OPN-negative MM patients in regard to the mean % of plasmocytosis, the stage of disease and the presence or absence of osteolytic lesions (P ¼ NS) ( Table 1) .
As we have previously published, 6 also in this cohort of patients analyzed, we found that the number of microvessels per field was higher in Ang-1-positive patients in comparison with Ang-1-negative ones (mean7s.e.: 7.5770.2 vs 3.2870.1; median: 6.21 vs 3.05; P ¼ 0.0017) and the MVD was significantly increased (35.6371.7 vs 14.9971.3, median: 31.72 vs 13.04; P ¼ 0.03). A multivariate analysis (performed by SPSS 10.0 Mac software) showed that both Ang-1 and OPN expression by CD138 þ MM cells significantly correlated with BM angiogenesis (MVD and number of vessels /field) (Po0.05) with a tighter correlation for Ang-1.
Discussion
In this study we show that human myeloma cells express and produce OPN and we have demonstrated for the first time that OPN is involved in myeloma-induced angiogenesis. Higher OPN levels have been previously reported in peripheral and BM samples of MM patients, 20, 21 and the production of OPN has been observed in BM mononuclear cells and BMSC of MM patients 20 at higher intensity as compared to MGUS subjects. 21 However, the direct production of OPN by myeloma cells has not been completely clarified in these studies. In our study, first we confirmed that HMCLs produce OPN; moreover, we have evaluated OPN mRNA and protein expression in fresh purified MM cells of a large cohort of MM patients in stage I-III showing that about 40% of patients express and produce OPN. We did not find any difference in OPN expression between BMSC of MM patients and normal subjects, whereas we found that OPN levels were significantly higher in BM plasma of MM patients positive for OPN as compared to normal controls. On the contrary, MM patients negative for OPN had no significantly higher OPN levels as compared to normal subjects. These observations suggest that the direct production of OPN by myeloma cells significantly contributes to the higher OPN BM Pro-angiogenic effect of OPN in multiple myeloma S Colla et al levels. Recently, it has been also demonstrated that osteoclastic cells produce a large amount of OPN, 22 suggesting that these cells may be another source of OPN in MM patients.
OPN is a multifunctional matrix associated protein that has a key role in tumor growth, progression and metastasis formation. [16] [17] [18] [19] OPN enhances tumoral cell proliferation increasing the malignant phenotype 16, 17, 25, 26 and its downregulation in cancer cells reduces their growth and tumorigenicity in mice. 27 In line with these observations we found that OPN enhances HMCLs proliferation and increases IL-6 proproliferative effect on myeloma cells. Moreover, we have demonstrated that IL-6 is able to upregulate OPN production by myeloma cells as well as the growth factor IFG-I even if to a minor extent. A cooperative effect of OPN and IL-6 on myeloma cell growth has recently been demonstrated in a coculture system between myeloma cells and osteoclastic cells. 28 In addition, it has also been demonstrated that IL-6 increases CD44 expression on myeloma cells, 29 indicating that IL-6 could increase their sensitivity to OPN. All these observations suggest that OPN may act as both an autocrine and a paracrine factor for myeloma cells and that a potential loop between IL-6 and OPN could be able to sustain myeloma cell growth. A prosurvival effect of OPN has also been described in pro-B cell lines. 30 In this system, the interaction of OPN with its receptor CD44 stimulated cell proliferation and inhibited cell apoptosis. 30 On the other hand, we failed to find any effect of OPN on myeloma cell survival in line with other recent evidences. 21 OPN has also been identified as a proangiogenic factor because it is able to promote endothelial cell migration and survival 13, 14 and the adhesion of both endothelial and smooth cells. 15 Moreover, OPN showed a potent proangiogenic effect in chick embryo choroallantoic membranes 31 and OPN-transfected cells significantly induced neo-vascularization in mice. 14 OPN has been associated with tumoral angiogenesis in mouse model 13, 14 and in human solid tumors. [17] [18] [19] In lung adenocarcinoma, it has been demonstrated that double OPN and VEGFpositive tumors have higher MVD as compared to those negative. 19 In our study, we demonstrate for the first time the involvement of OPN in the angiogenic process that occurs in MM patients. In fact we show that OPN produced directly by MM cells is critical in the stimulation of endothelial cells in an in vitro model of angiogenesis as demonstrated by the lack of proangiogenic effect of OPN-immunodepleted CM of myeloma cells and by the capacity of anti-OPN Ab to block myelomainduced angiogenesis. In the same system, blocking anti-VEGF and anti-Tie2 Abs also inhibited myeloma-induced angiogenesis suggesting that VEGF and Ang-1 are also critical in this process, as previously published. 6 Moreover, we have demonstrated that OPN-positive MM patients have a significantly higher MVD and number of microvessels for field as compared to OPN-negative ones. This observation supports the in vitro results confirming the potential role of OPN as a direct proangiogenic factor in MM. It could also be possible that OPN contributes to the increase of BM angiogenesis in MM indirectly through the modulation of matrix metalloproteinase-2 (MMP-2) because it has been demonstrated that OPN increases MMP-2 expression and activates pro-MMP-2 in tumor cells. 32 Consistently, higher MMP-2 expression and activity have been demonstrated in myeloma cells 33 and in MM patients with an increased angiogenesis as compared to MGUS subjects. 1 Since almost all MM patients tested in our study were positive for VEGF, the production of OPN could discriminate patients with higher angiogenesis. Clearly, other molecules could be critical in the identification of MM patients with higher angiogenesis. Recently, we have published that myeloma cells also produce the angiogenetic molecule Ang-1 and that patients positive for Ang-1 have an increased BM angiogenesis as compared to those negative. 6 In the present paper, we have also compared the OPN expression in MM patients with the expression of other proangiogeneic factors. We found that VEGF expression does not discriminate multiple myeloma patients with high and low bone marrow angiogenesis because it was expressed in almost all patients. On the contrary, we observed that both Ang-1 and OPN expression is significantly correlated with BM angiogenesis. Clearly this observation should be confirmed in a larger cohort of patients.
Plasma OPN levels have been previously correlated with bone disease in MM patients; 20 on the other hand, we failed to find a correlation between the direct production of OPN by MM patients and the presence of bone lesions. Thus, our data seem to indicate that the production of OPN by myeloma cells is critical for the angiogenic process rather than for the bone resorption, even if we cannot exclude a role of OPN in osteoclast activation in MM given that OPN stimulates osteoclast adhesion and migration. 34 Finally, the mechanism by which myeloma cells produce OPN has been evaluated in this study showing that Runx2/Cbfa1 transcription factor is expressed and active in myeloma cells and correlates with OPN production by myeloma cells. Runx2/Cbfa1 is a transcription factor that belongs to the runt family and it is highly restricted to cells of osteoblastic lineage 11, 35 because it has a pivotal role in osteoblast formation and differentiation. 35 However, it has been demonstrated that Runx2/Cbfa1 is also expressed by mammary epithelial cells and by breast cancer cells where it represents the major transcription factor that regulates OPN production, 9,10 as demonstrated by the capacity of the dominant negative form of Runx2/Cbfa1 to repress endogen OPN production. 9 In line with these observations, we have demonstrated for the first time the expression and activity of Runx2/Cbfa1 in human myeloma cells. The presence of Runx2/Cbfa1 in myeloma cells could also regulate, other than OPN, the ectopic production of other bone proteins, as osteocalcin produced by the HMCLs NCI-H929. 36 The expression of the Runx2/Cbfa1 gene is regulated by at least two distinct promoters that generate two mRNA transcripts, and additional Cbfa1 isoforms may arise as the result of the differential use of transcriptional start sites or alternative splicing. 11, 37 Both isoforms are involved in OPN expression in mouse bone cells, whereas in human BMSC it has been demonstrated only in the presence of the isoform II. 37 In our study we show that HMCLs express Runx2/Cbfa1 isoform II but not the isoform I. The role of Runx2 in OPN production by human myeloma cells was clearly demonstrated in the present paper by the experiments of transfection with siRNA anti-Runx2 that were able to block OPN mRNA expression and protein production. Other transcription factors could regulate OPN expression in myeloma cells given that a transcriptional regulation of OPN promoter by C/EBPa and to a minor extent by AML-1 in metastatic cancer cells has recently been demonstrated. 12 In this study, we have tested C/EBPa mRNA expression in several HMCLs but we failed to detect it, demonstrating that C/EBPa is not involved in OPN production by myeloma cells. On the other hand, we found that myeloma cells express the two major isoforms of the transcription factor AML-1, AML-1A and AML-1B, as previously described, 38 even if any correlation between OPN expression and AML-1 expression or AML-1A/AML-1B ratio has not been found. Moreover, we failed to observe a significant activity of AML-1 in human myeloma cells. This suggests that AML-1 probably is not the main transcription factor regulating OPN expression in myeloma cells even if we cannot exclude its contribution in the regulation of OPN production together with Runx2/Cbfa1.
